The DOI matches its Crossref record; 352 of the 353 references it cites were found in a registry or an index.
From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aminopterin is the precursor of the currently used drugs methotrexate and pemetrexed, both of which are folate analogues that inhibit one-carbon transfer reactions required for de novo nucleotide synthesis (Figure 1, Figure 2a)(Walling, 2006).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Walling, 2006
Citations
Cites
Polychemotherapy for early breast cancer: an overview of the randomised trials
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 3,126
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,169
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
Bonadonna, G., Brusamolino, E., Valagussa, P., Rossi, A., Brugnatelli, L., Brambilla, C., Lena, M. D., Tancini, G., Bajetta, E., Musumeci, R., et al. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602192940801 · Cited by 1,329
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., & Brambilla, C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321401 · Cited by 1,048
Loehrer, P. J., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P. J., Tannock, I. F., Raghavan, D., Stuart‐Harris, R., Sarosdy, M. F., & Lowe, B. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1066 · Cited by 981
A Southwest Oncology Group study
Jenkins, T. R., Tangen, C. M., Macdonald, J. S., Weiss, G. R., Chapman, R. M., & Hantel, A. (1993) · Cited by 773
Flagged first, then by citations
1 of the 353 references couldn’t be matched to a known paper.
Research works printed but not linked: 25
- Li MC, Hertz R, Spence DB: Effect of methotrexate therapy on choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 93:Abstract 361, 1956 · DOI
- Allegra CJ: In: Chabner BA, Collins JM (eds) Antifolates in Cancer Chemotherapy Principles and Practice. Lippincott, 1990, pp. 110–152
- Ross JF, Chaudhuri PK, Ratnam M: Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer Res 73:2432–2434, 1994
- Bruckner HW, Lokich JJ, Stablein DM: Studies of Bakers antifol, methotrexate and razozane in advanced gastric cancer: A Gastrointestinal Tumour study group report. Cancer Treat Rep 66:1713–1717, 1982
- Gesme DH Jr, Jett JR, Schreffler DD, Su JQ, Maillard JA, Foley JF, KrookJE, Maksymiuk AW, Hatfield AK, Ebbert LP: A randomized phase II trial of amonafide or Trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group. Cancer 71(9):2723–2726, 1993
- Blanke CD, Kasimis B, Schein P. Capizzi R, Kurman M: Phase II study of trimetrexate, fluorouracil and leucovorin for advanced colorectal cancer. J Clin Oncol 15:915–920, 1997 · DOI
- Casper ES, Christman KL, Schwartz GK, Johnson B, Brennan MF, Bertino JR: Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma. Cancer 72(3):766–770, 1993
- Schornagel JH, Verweij J, de Mulder PH, Cognetti F, Vermorken JB, Cappelaere P, Armand JP, Wildiers J, de Graeff A, Clavel M: Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cooperative Group study. J Clin Oncol 13(7):1649–1655, 1995 · DOI
- Gralla RJ, Lee JS, Kris MG, Comis RL, Sridhar KS, Crawford J, Hirsh V, Wernz JC, Belani CP, Vokes E: Multicenter, randomized trial comparing the combination of edatrexate, mitomycin and vinblastine (EMV) with mitomycin and vinblastine (MV) in 673 patients with stage III and IV non-small cell lung cancer. Abstract. Proc Am Soc Clin Oncol 13:1161, 1994
- Pazdur R, Vincent M: Raltitrexed (Tomudex) versus 5 fluorouracil and leucovorin (5FU +LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter, North American Trial. Abstract. Proc Am Soc Clin Oncol 16:801, 1997
- Douillard J, Michel P, Gamelin E, Conroy T, Francois E, Raoul J, Becouarn Y, Bertheault F Cvitkovic S, Nasca S, Ychou M, Fandi A, Seitz J: Raltitrexed (Tomudex) plus oxaliplatin: An active combination for first line chemotherapy in patients with metastatic colorectal cancer. Abstract. Proc Am Soc Clin Oncol 19:971, 2000
- Van Laethem JL, Van Maele Ph, Polus M, Demols A, Houbiers Gh, Leleux A, Schurmans P, D'Haens G, Recloux P, Caenepeel P, Ryssaert T, Daems K, Verslype C, Van Cutsem E, Peeters M: Raltitrexed (Tomudex) and gemcitabine (Gemzar) in advanced pancreatic carcinoma: A Belgian multicenter phase II study. Abstract. Proc Am Soc Clin Oncol 21:547, 2002
- Decreux M, Fizazi K, Daniel C, Ruffie P, Kabouche A, Fandi A, Smith M, Armand JP: Updated results of a phase I trial of tomudex (T) in combination with oxaliplatin (L-OHP) in advanced solid tumors: A promising and active combination. Abstract. Ann Oncol 9 (suppl 4):6020, 1998
- Mani S, Rosen L, Bennet P, Dancey J, Conner S, Johnston A, Clendeninn N: A phase II trial of nolatrexed dihydrochloride (Thymitaq, AG337) in patients with advanced hepatocellular carcinoma. Abstract. In: Proc 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy: 1998, p 619
- Grindey GB, Alati T, Lantz R, Pohland R, Shih C: Role of dietary folic acid in blocking the toxicity but not the antitumor activity of lometrexol. Abstract. In: Proc Am Assoc Can Res 32:1921, 1991
- Grindey GB, Alati T, Lantz R, Pohland R, Shih C: Role of dietary folic acid in blocking the toxicity but not the antitumor activity of lometrexol (DDATHF). Abstract. In: Proc NCI-EORTC Symposium on New Drugs in Cancer Therapy: 1992, p 216
- Wedge SR, Laohavinij S, Taylor GA, Boddy A, Calvert AH, Newell DR: Clinical pharmacokinetics of the antipurine antifolate (6R) -5, 10-dideazatetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clin Cancer Res 1:1479–1486, 1995
- Nelson R, Butler F, Dugan W Jr, Davis-Land M, Stone M, Dyke R: Phase I clinical trial of LY 264618 (Dideazatetrahydrofolic acid: DDATHF). Abstract. In: Proc Am Soc Clin Oncol 9:76, 1990
- Ayelsworth C, Baker SD, Stephenson J, Monroe P, Sanchez I, Walling J, Johnson R, Von Hoff D, Rowinsky E: Phase I and pharmacokinetic (pk) study of the glycinamide ribonucleotide formyltransferase (GARFT) inhibitor LY309887 as a bolus every 3 weeks with folic acid (FA). Abstract. In: Proc Am Soc Clin Oncol 17:865, 1998
- Halford S, Harper P, Highley M, Lind M, Calvert AH, Johnson R, Walling J: A Phase I and pharmacokinetic study of LY309887 given ever 3 weeks with folic acid supplementation. Abstract. In: Proc Am Soc Clin Oncol 18:652, 1999
- Kindler H, Dugan W, Hochster H, Strickland D, Jacobs A, John W J. Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine. Abstract. In: Proc Am Soc Clin Oncol 21:499, 2002
- Atkins JN, Jacobs S, Wieand S, Smith R, John W, Renshaw G, Colangelo L., Geyer C Jr., Wolmark N: Pemetrexed and oxaliplatin for first line treatment of patients with advanced colorectal cancer: A phase II trial of the NSABP foundation research program. Abstract. Proc Am Soc Clin Oncol 22:1108, 2003
- Paz Ares L, Tabemoro J, Moyano A, Rifa J, Alonso J, Marcuello E, Gonzalez A, Castellano D, Hermandez S, Cotes-Funes H, Doce H: Significant activity of the multitargeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: Results of a phase II trial. Abstract. Ann Oncol 9 (suppl 4):291, 1998
- Goedhals L, van Wijk AL: MTA (LY231514) in advanced carcinoma of the cervix. Abstract. Ann Oncol 9 (suppl 4):339P, 1998
- Vogelzang NJ, Emri S, Boyer MJ, Gatzemeier U, Jablons D, Taub R, Paul S, Shah P, Nguyen B: Effect of folic acid and vitamin b12 supplementation on risk benefit ratio from phase III study of pemetrexed + cisplatin versus cisplatin in malignant pleural mesothelioma. Abstract. In: Proc Am Soc Clin Oncol 22:2644, 2003
Cited by
Sorted by citations
Items 101–184 of 184
Brody, J. R., & Gallmeier, E. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.8.2976 · Cited by 14
Ogrodzinski, M. P., Teoh, S. T., & Lunt, S. Y. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1666 · Cited by 13
Michalak, O., Gruza, M. M., Witkowska, A. B., Bujak, I., & Cmoch, P. (2015) · Molecules · doi:10.3390/molecules200610004 · Cited by 13
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity
Tuffaha, H., & Omar, S. A. (2009) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155209348720 · Cited by 13
van der Heijden, J., Assaraf, Y. G., Gerards, A., Oerlemans, R., Lems, W. F., Scheper, R. J., Dijkmans, B. A. C., & Jansen, G. (2013) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2013.797490 · Cited by 13
Enyedy, É. A., Farkas, E., Dömötör, O., & Santos, M. A. (2010) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2010.12.008 · Cited by 13
Heyman, B. M., & Beaven, A. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.07.283 · Cited by 12
Hayano, A., Takashima, Y., & Yamanaka, R. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01451-9 · Cited by 12
Kawami, M., Honda, N., Miyamoto, M., Yumoto, R., & Takano, M. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13022 · Cited by 12
Lisowska, M., Milczarek, M., Ciekot, J., Kutkowska, J., Hildebrand, W., Rapak, A., & Miążek, A. (2019) · Cancers · doi:10.3390/cancers11101438 · Cited by 11
Yamashita, K., Kiyonari, S., Tsubota, S., Kishida, S., Sakai, R., & Kadomatsu, K. (2020) · Cancer Science · doi:10.1111/cas.14485 · Cited by 10
Peters, G. J., Kathmann, I., Giovannetti, E., Smid, K., Assaraf, Y. G., & Jansen, G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1450418 · Cited by 10
Adewale, O. O., Wińska, P., Piasek, A. M., & Cieśla, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212202 · Cited by 11
Okamoto, I., Shimizu, T., Miyazaki, M., Tsurutani, J., Ichikawa, Y., Terashima, M., Takeda, M., Fumita, S., Ohki, E., Kimura, N., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9565-5 · Cited by 10
Thomas, H. D., Saravanan, K., Wang, L.-Z., Lin, M., Northen, J. S., Barlow, H. C., Barton, M., Newell, D. R., Griffin, R. J., Golding, B. T., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1208 · Cited by 9
In Vitro Effect of Neopterin on Erythropoiesis in Mice
Tsuboi, I., Hokari, T., Harada, T., Yuda, M., & Aizawa, S. (2009) · Pteridines · doi:10.1515/pteridines.2009.20.1.115 · Cited by 9
Capparelli, P. N. E. (2015) · Journal of Pharmacovigilance · doi:10.4172/2329-6887.1000157 · Cited by 8
Label-Free Target Identification Reveals the Anticancer Mechanism of a Rhenium Isonitrile Complex
Yim, J., & Park, S. B. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.850638 · Cited by 8
Yu, W., Tang, L., Lin, F., Yao, Y., & Shen, Z. (2014) · Oncology Letters · doi:10.3892/ol.2014.2472 · Cited by 8
QSAR Modelling of Thymidylate Synthase Inhibitors in a Series of Quinazoline Derivatives
Хайруллина, В. Р., Gerchikov, A. Y., Lagunin, A. A., & Зарудий, Ф. С. (2018) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-018-1710-z · Cited by 8
Repurposing payloads: next generation of antibody–drug conjugates
Shatzer, K., & Müller, F. L. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.04.001 · Cited by 8
Targeting thymidylate synthase by antifolate drugs for the treatment of cancer
Jackman, A. L., Forster, M. D., & NG, M. M. (2008) · Elsevier eBooks · doi:10.1016/b978-012369448-5.50012-4 · Cited by 7
Çeşme, M., & Gölcü, A. (2019) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-019-02011-1 · Cited by 6
Leeuwenburgh, V. C., Urzúa-Traslaviña, C. G., Bhattacharya, A., Walvoort, M. T. C., Jalving, M., de Jong, S., & Fehrmann, R. S. N. (2021) · Cancer & Metabolism · doi:10.1186/s40170-021-00272-7 · Cited by 5
Vásquez, A. F., Gómez, L. A., Barrios, A. F. G., & Riaño‐Pachón, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213946 · Cited by 5
Relationship between the efficacy and adverse effects of methotrexate and gene polymorphism
Zhao, X., Wu, P., Yang, Z., & Miao, R.-R. (2024) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-024-00562-x · Cited by 5
Rushworth, D., Alpert, A., Carrero, R. M. S., Olivares, S., Spencer, D. M., & Cooper, L. J. N. (2015) · Gene Therapy · doi:10.1038/gt.2015.88 · Cited by 5
Kobe, H., Ito, A., Hayata, H., Nishimura, K., Ueda, Y., & Ishida, T. (2020) · Internal Medicine · doi:10.2169/internalmedicine.5027-20 · Cited by 5
Metabolic drivers of genome instability in cancer: mechanisms and therapeutic opportunities
Wang, Y.-S., Qian, L.-H., Liu, C., & Yu, K. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00775-3 · Cited by 4
PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma
Paras, K. I., Brunner, J. S., Boyer, J. A., Montero, A. M., Jackson, B. T., Chakraborty, S., Xie, A., Guillan, K. C., Siddiquee, A. H., Torres, L. P., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0315 · Cited by 4
The pharmacotherapeutics of sarcoidosis
Mangialardi, P., Harper, R. W., & Albertson, T. E. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2032657 · Cited by 4
Engineered biomaterial delivery strategies are used to reduce cardiotoxicity in osteosarcoma
Hou, Y., Wang, J., & Wang, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1284406 · Cited by 4
Hydrogen-bonded supramolecular assemblies of folic acid with simple hexoses
Ceborska, M., Dąbrowa, K., Cędrowski, J., & Zimnicka, M. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131904 · Cited by 4
Wang, M., Tian, C., Xue, L., Li, H., Cong, J., Fang, F., Yang, J., Yuan, M., Chen, Y., Guo, Y. Q., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112113 · Cited by 4
Folate Receptor Targeted Thymidylate Synthase Inhibitors
Jackman, A. L., Jansen, G., & NG, M. M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-8417-3_5 · Cited by 4
Panicker, V. V., Radhakrishnan, S. E., Kuruttukulam, G. V., Bose, J. A., & Favas, T. T. (2024) · Cureus · doi:10.7759/cureus.51542 · Cited by 3
Ragab, S. M., & Badr, E. A. E. (2015) · Hematology · doi:10.1179/1607845415y.0000000042 · Cited by 3
Personalized medicine of methotrexate therapy
de Rotte, M. C. F. J., Boer, E. D., Bulatović-Ćalasan, M., Bulatović-Ćalasan, M., Heijstek, M. W., Winkel, M. L. T., Heil, S. G., Lindemans, J. W., Jansen, G., Peters, G. J., et al. (2012) · Pure Amsterdam UMC · Cited by 3
Folate Receptor-Targeted Radionuclide Imaging Agents
Müller, C., & Schibli, R. (2011) · Springer eBooks · doi:10.1007/978-1-4419-8417-3_4 · Cited by 3
Les métastases des cancers urothéliaux : place de la chimiothérapie
Lebrét, T., & Méjean, A. (2008) · The French Journal of Urology · doi:10.1016/s1166-7087(08)74554-8 · Cited by 3
Dai, E., Wang, J., Yang, F., Zhou, X., Song, Q., Wang, S., Yu, X., Liu, D., Yang, Q., Dai, H., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31158 · Cited by 3
Positioning pemetrexed in the treatment of ovarian cancer
Ledermann, J. A., & Stebbing, J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.02.006 · Cited by 3
Folates and antifolates in rheumatoid arthritis
Jansen, G., Weijers, K., Blits, M., van der Heijden, J. W., Gent, Y. Y. J., Al, M., van der Laken, C. J., Molthoff, C. F. M., Verweij, C. L., Voskuyl, A. E., et al. (2013) · Pteridines · doi:10.1515/pterid-2013-0012 · Cited by 2
Quelles nouvelles à propos des antimétabolites en oncologie?
Lansiaux, A. (2007) · ONCOLOGIE · doi:10.1007/s10269-007-0768-0 · Cited by 2
Potential for α-Folate Receptor-Targeted Treatment for Ovarian Cancer
Ng, C. H. M., & Jackman, A. L. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7216-3_12 · Cited by 2
Bentur, Y., & Lurie, Y. (2016) · Springer eBooks · doi:10.1007/978-3-319-20790-2_109-1 · Cited by 2
Metabolic dysregulation in cancer progression
Arfin, S., Agrawal, K., Kumar, A., Kumar, A. J., Rathi, B., & Kumar, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99879-6.00008-0 · Cited by 2
Carrero, Y. N., Moya, J., Ganán, M. A. A., & Mosquera-Sulbarán, J. (2022) · Investigación Clínica · doi:10.54817/ic.v63n1a01 · Cited by 1
Kong, D., & Dolzhenko, A. V. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_229 · Cited by 1
Csordás, K., Eipel, O., Hegyi, M., Csóka, M., Pap, É., & Kovács, G. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29143 · Cited by 1
Vujić, T., Davidović-Plavšić, B., Uletilović, S., Šatara, S. S., Samardžić, J. P., & Saničanin, Ž. (2014) · Contemporary Materials · doi:10.7251/comen1401146v · Cited by 1
Targeting DMARD resistance in Rheumatoid Arthritis
van der Heijden, J. W. (2008) · Pure Amsterdam UMC · Cited by 1
Afshar, A., Khoradmehr, A., Zare, M., Baghban, N., Mohebbi, G., Barmak, A., Khatami, M., Mahmudpour, M., Daneshi, A., Bargahi, A., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-835233/v1 · Cited by 1
Afshar, A., Khoradmehr, A., Zare, M., Baghban, N., Mohebbi, G., Barmak, A., Khatami, M., Mahmudpour, M., Daneshi, A., Bargahi, A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-835233/v2 · Cited by 3
ACTIVE EFFLUX TRANSPORT AND CNS DISTRIBUTION OF THE NOVEL ANTIFOLATE PEMETREXED
Li, L. (2010) · University of Minnesota Digital Conservancy (University of Minnesota)
Jönsson, P. (2008) · Lund University Publications (Lund University)
Methotrexat für die topische Applikation in magistraler Rezeptur
Wohlrab, J., Neubert, R. H. H., Michael, J., & Naumann, S. (2015) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.40_12622
Rebula, G., Rebula, A., Zaletel, P., Srdić, V., & Zagorc, M. (2014) · Спортске науке и здравље - АПЕИРОН · doi:10.7251/ssh1402110r
PROBLEMI IZGRADNJE I UREĐENJA SPORTSKO-REKREACIONO-TURISTIČKOG CENTRA „TOPLICA“ ŽIVINICE
Mujagić, N. (2016) · PRIMUS - INFORMATIKA PRAVO EKONOMIJA BANKARSTVO · doi:10.7251/pmg0115073m
Ogrodzinski, M. P., Teoh, S. T., & Lunt, S. Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.19.049577
Methionine synthase supports tumor tetrahydrofolate poolsPreprint
Wang, J. Z., Ghergurovich, J. M., Yang, L., & Rabinowitz, J. D. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.05.284521
Robust metabolic transcriptional components in 34,494 patient-derived samples and cell linesPreprint
Leeuwenburgh, V. C., Urzúa-Traslaviña, C. G., Bhattacharya, A., Walvoort, M. T. C., Jalving, M., de Jong, S., & Fehrmann, R. S. N. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.01.321950
Robust Metabolic Transcriptional Components in 34,494 Patient-Derived Samples and Cell LinesPreprint
Leeuwenburgh, V. C., Urzúa-Traslaviña, C. G., Bhattacharya, A., Walvoort, M. T. C., Jalving, M., de Jong, S., & Fehrmann, R. S. N. (2021) · Research Square · doi:10.21203/rs.3.rs-659596/v1
Villarreal, B., & Nadilly, Y. (2021) · Figshare
Khadela, A. D., Vyas, B., & Joshi, S. V. (2021) · Journal of Integrated Health Sciences · doi:10.4103/jihs.jihs_13_21
Bentur, Y., & Lurie, Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-17900-1_109
Aujayeb, A. (2017) · International Journal of Pharmacovigilance · doi:10.15226/2476-2431/2/1/00116
Vujić, T., Davidović-Plavšić, B., Uletilović, S., Šatara, S. S., Samardžić, J. P., & Saničanin, Ž. (2015) · Contemporary Materials · doi:10.7251/comen1501074v
Ogrodzinski, M. P., Teoh, S. T., & Lunt, S. Y. (2023) · doi:10.1158/0008-5472.c.6512697.v1
Drugs Used Post stem Cell Transplant
Sharma, S. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-5802-1_36
Innovative Discovery Studies of Anti Lungs Cancer Active Drug Substances in Medicinal Chemistry
Narayanamoorthy, B., & Ravichandran, C. (2024) · INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT · doi:10.55041/ijsrem38564
NN‐Enriched Nucleoside Analogs
Wauchope, O. R. (2025) · Patai's chemistry of functional groups · doi:10.1002/9780470682531.pat1018
Synthesis and In Vitro Pharmacological Evaluation of 5,8-Dideaza Analogs of Methotrexate
Abellán-Flos, M., Skarbek, C., Gibbons, D., Rascol, E., García, A., & Labruère, R. (2025) · Molecules · doi:10.3390/molecules30132772
Choed-Amphai, C., Khorana, J., Sathitsamitphong, L., Maneekesorn, S., Chanthong, S., Natesirinilkul, R., & Charoenkwan, P. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251403953
Leeuwenburgh, V. C., Urzúa-Traslaviña, C. G., Bhattacharya, A., Walvoort, M. T. C., Jalving, M., de Jong, S., & Fehrmann, R. S. N. (2021) · Figshare · doi:10.6084/m9.figshare.16683141
Paradoxical oncogenic effects of hepatic Brca1 through modulating Bhmt
Ghebreselassie, M., Park, Y. J., Nakib, D., Dodington, D. W., Patel, P. S., Won, S., Hakem, A., Hakem, R., MacParland, S. A., & Woo, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-39581-6
Xue, J., Deng, J., Qin, H., Li, Y., Jing, Z., Zhao, Z. Y., & Wang, H. (2026) · Discover Oncology · doi:10.1007/s12672-026-05365-7
BindingDB Entry 50013257: Design, synthesis and biological activity of N
BindingDB (2022) · UC San Diego · doi:10.7270/q2dj5kcq
Vujić, T., Davidović-Plavšić, B., Uletilović, S., & Saničanin, Ž. (2014) · GLASNIK HEMIČARA TEHNOLOGA I EKOLOGA REPUBLIKE SRPSKE · doi:10.7251/ghte1410029v
SELECTION METHODS FOR GENETICALLY-MODIFIED T CELLS: IN SUPPORT OF TRANSLATIONAL THERAPY
Rushworth, D. (2015) · Digital Commons-TMC (Texas Medical Center)
Metadata
- Authors
- Walling, J.
- Affiliations
- University of Bristol (GB)
- Corresponding author
- Walling, Jackie
- ORCID
- Walling, Jackie
- Venue
- Investigational New Drugs
- Published
- 2006-01
- Volume
- 24
- Issue
- 1
- Pages
- 37-77
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W1993777583
- Cited by
- 182
- References
- 353
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 9 · 2023: 4 · 2022: 11 · 2021: 15 · 2020: 12 · 2019: 10 · 2018: 7 · 2017: 7 · 2016: 8 · 2015: 17 · 2014: 9 · 2013: 7 · 2012: 8
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Investigational New Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- antifolate, methotrexate, pemetrexed, pharmacodynamics, clinical properties
- MeSH terms
- Pemetrexed, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Biological Transport, Folic Acid Antagonists, Glutamates, Guanine, Humans, Methotrexate, Neoplasms, Randomized Controlled Trials as Topic, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
